Article in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors.
Jenny ChenDepartment of Medicine, University of Louisville School of Medicine, Louisville, KY 40202, USA.
Fengyuan LiDepartment of Medicine, University of Louisville School of Medicine, Louisville, KY 40202, USA.
Jiyeon LeeDepartment of Medicine, University of Louisville School of Medicine, Louisville, KY 40202, USA.
Md ManirujjamanDepartment of Structural and Cellular Biology, Tulane University School of Medicine, New Orleans, LA 70112, USA.ORCID 0000-0003-0912-7369
Lihua ZhangDepartment of Medicine, University of Louisville School of Medicine, Louisville, KY 40202, USA.
Zhao-Hui SongDepartment of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY 40202, USA.
Craig McClainDepartment of Medicine, University of Louisville School of Medicine, Louisville, KY 40202, USA.ORCID 0000-0002-7219-8939
Wenke FengDepartment of Medicine, University of Louisville School of Medicine, Louisville, KY 40202, USA.
Funding
Role of oxidized linoleic acid metabolites in the pathogenesis of alcoholic liver diseaseP20GM113226 · NIGMS · UNIVERSITY OF LOUISVILLE · PI GHARE, SMITA S · 2016 to 2025
$24.1M
The Role of Nutrition in the Development/Progression of Alcohol-Induced Organ InjuryP50AA024337 · NIAAA · UNIVERSITY OF LOUISVILLE · PI SHIRISH S BARVE · 2016 to 2026
$17.9M
Mechanisms of Probiotics in Alcoholic Liver DiseaseR01AA023190 · NIAAA · UNIVERSITY OF LOUISVILLE · PI FENG, WENKE · 2015 to 2024
$3.5M
Intestine FXR activation by LGG-derived nanoparticles in alcohol-associated liver diseaseR01AA030424 · NIAAA · UNIVERSITY OF LOUISVILLE · PI WENKE FENG · 2022 to 2026
$2.6M
Cannabidiol as a treatment for alcoholic liver diseaseR21AA031172 · NIAAA · UNIVERSITY OF LOUISVILLE · PI FENG, WENKE, SONG, ZHAO-HUI · 2023 to 2023
Previous research highlighted the involvement of the cannabinoid CB1 receptor in regulating the physiology of hepatocytes and hepatic stellate cells. The inhibition of the CB1 receptor via peripherally restricted CB1 receptor inverse agonist JD5037 has shown promise in inhibiting liver fibrosis in mice treated with CCl4. However, its efficacy in phospholipid transporter-deficiency-induced liver fibrosis remains uncertain. In this study, we investigated the effectiveness of JD5037 in
Indexed as
ATP-Binding Cassette Sub-Family B Member 4ATP Binding Cassette Transporter, Subfamily BLiver CirrhosisReceptor, Cannabinoid, CB1AnimalsBile Acids and SaltsDrug Inverse AgonismLiverMaleMiceMice, Inbred C57BLMice, KnockoutATP-Binding Cassette Sub-Family B Member 4ATP Binding Cassette Transporter, Subfamily BBile Acids and SaltsReceptor, Cannabinoid, CB1Cannabinoidsliver fibrosis
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Peripherally Restricted CB1 Receptor Inverse Agonist JD5037 Treatment Exacerbates Liver Injury in MDR2-Deficient Mice. · full record | OpenQuestion